The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Outcome Measures, 2022LRRK2 Kinase Activity and Global Proteomic Biomarkers in the Gut of Patients with Parkinson’s and/or Inflammatory Bowl Disease
Study Rationale: Accumulative evidence suggests a strong connection between the brain and the gut, with chronic intestinal inflammation being linked to an increased risk of Parkinson’s disease (PD)...
-
2022: Accelerated Therapeutics Program, 2022Preclinical and Early Clinical Development of NPT1220-478 for the Treatment of Parkinson's Disease
Study Rationale: Parkinson’s disease is a progressive neurodegenerative disorder; meaning that from its inception, neurons are continuously dying with resulting worsening of neurologic symptoms. Two...
-
Fall 2021 RFA: Promoting Diversity, Equity and Inclusion in Parkinson’s Disease Research, 2022Preventing Fractures in Parkinson’s Disease by Identifying Barriers to Care and Social Determinants of Health
Study Rationale: Compared with the general population, people with Parkinson’s disease (PD) are more likely to fall and break a bone as a result of disease-related motor issues, such as difficulty...
-
Alpha-synuclein Seed Amplification Assay Program, 2022Maximizing the Sensitivity of Seed Amplification Assays Used to Detect Alpha-synuclein Aggregates
Study Rationale: One characteristic of Parkinson’s disease (PD) is the aggregation of proteins such as alpha-synuclein in the brain. To diagnose PD, it is important to be able to detect such...
-
Research Grant, 2022Using a Systems-based Approach to Study the Molecular Processes Underlying Parkinson’s Disease: The Foundational Data Initiative
Study Rationale: This effort aims to produce foundational data that will provide immediate insight and a resource for understanding the molecular basis of Parkinson disease (PD). The work, conducted...
-
Alpha-synuclein Seed Amplification Assay Program, 2022Comparison and Cross-Validation of Alpha-synuclein Seed Aggregation Assays in Samples of Skin, Cerebrospinal Fluid, Saliva and Tears
Study Rationale: Identification of misfolded alpha-synuclein aggregates in postmortem brain samples remains a major histopathological hallmark for confirming the diagnosis of Parkinson’s disease (PD)...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.